- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01098006
A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Brussels, Belgien, 1070
- GSK Investigational Site
-
Bruxelles, Belgien, 1000
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Written informed consent obtained from the subject.
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- A male or female between, and including, 18 and 65 years of age at study start.
- Evidence of chronic hepatitis B infection as per medical record.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start.
In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records:
Group A: Immune tolerant patients
- Viral load: > 2x107 IU/mL of HBV DNA
- HBeAg positive
- Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients
- Viral load: > 2x104 IU/mL of HBV DNA
- HBeAg positive
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C: Healthy carriers
- Viral load: not exceeding 2x103 IU/mL of HBV DNA
- HBeAg negative
- Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients
- Viral load: > 2x103 IU/mL of HBV DNA
- HBeAg negative
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy
Exclusion Criteria:
- Any hepatitis B specific treatment prior to blood sampling at Visit 1.
- Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol.
- Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1.
- Receipt of blood products within 120 days prior to study entry (Visit 1).
- Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).
- Receipt of interferon within 120 days prior to study entry (Visit 1).
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required).
- Pregnant or lactating female.
- History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone ≥10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.
- History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible).
- History of major congenital defect.
- Subjects with a history of, or current, alcohol or substance abuse.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Immune tolerant patients Group
Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Andet: HBeAg positive Group
HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Andet: Inactive carriers Group
Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Andet: HBeAg negative Group
HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Tidsramme: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 113854
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Immunologiske tests
-
Radiometer Medical ApSRekruttering
-
Wageningen UniversityUkendt
-
Duke UniversityNational Institute of General Medical Sciences (NIGMS)Afsluttet
-
University of TurkuAalto UniversityAfsluttetTest, virkelighedFinland
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenUkendtMateriale testBelgien
-
Centre Hospitalier Universitaire VaudoisIkke rekrutterer endnuFarmakogenetisk test
-
University of FloridaNational Center for Advancing Translational Sciences (NCATS)AfsluttetFarmakogenetisk testForenede Stater
-
Radiometer Medical ApSAfsluttetDiagnostisk testDanmark
-
University of MichiganAfsluttet
Kliniske forsøg med Blood withdrawal
-
University of Colorado, DenverRekrutteringEnkelt-ventrikel | Abnormitet i pulmonal vaskulær modstand | Metabolomics | Superior Cavo-pulmonal anastomose | EndotelinForenede Stater
-
ExThera Medical Europe BVExThera Medical Corporation; Vivantes Clinic NeuköllnRekrutteringBlodbaneinfektionFrankrig, Tyskland, Holland, Østrig, Belgien, Italien, Polen, Spanien, Det Forenede Kongerige
-
Ascensia Diabetes CareAfsluttet
-
Ascensia Diabetes CareAfsluttetDiabetesForenede Stater
-
Helios Klinik Gotha/OhrdrufHelios Klinikum ErfurtIkke rekrutterer endnu
-
Stanford UniversityRekrutteringKarsygdomme | Slag | Forhøjet blodtryk | TIAForenede Stater
-
Ascensia Diabetes CareAfsluttetDiabetesForenede Stater
-
University of British ColumbiaIkke rekrutterer endnuForhøjet blodtryk
-
Ascensia Diabetes CareAfsluttetDiabetesForenede Stater
-
University of the Balearic IslandsAfsluttetBlodtryk | ModstandstræningSpanien